#USA #Los Gatos #thrombectomy #Akura Medical #Katana System

Akura Medical Secures $53 Million in Series C Funding

Akura Medical, a notable company within the Shifamed portfolio, has announced the successful completion of a $53 million Series C funding round. This financial boost will be instrumental in further developing their innovative products aimed at transforming the care of venous thromboembolism (TEV), particularly with their flagship Katana™ Thrombectomy System and the NavIQ™ quantification software.

Funding Details

The funding round, primarily led by the Qatar Investment Authority (QIA) with contributions from existing investors, is set to accelerate various developmental activities. These include completing patient recruitment for their QUADRA-PE clinical trial and fulfilling regulatory milestones crucial for product advancement. A portion of these funds will also be allocated to establish a joint venture in Qatar, indicating Akura Medical's commitment to expanding its global reach.

Interim CEO Amr Salahieh expressed enthusiasm about the funding, remarking, "Akura Medical is in the process of shaping a differentiated portfolio of venous thrombectomy technologies aimed at enhancing procedural accuracy and improving patient outcomes. The recent introduction of our NavIQ quantification software signifies a significant step towards data-driven and intelligent thrombectomy procedures. This new capital will facilitate accelerated product development and form the foundation for long-term growth. We truly value the trust and partnership of QIA in achieving our vision."

Product Portfolio

Akura Medical's product suite focuses on advancing the field of thrombectomy. The standout Katana™ system is designed to effectively eliminate various types of blood clots while optimizing catheter placement and providing real-time data from sensors monitoring pulmonary artery pressure throughout the procedure. This integration of cutting-edge technology aims to enhance the effectiveness of thrombectomy procedures significantly.

On the other hand, the NavIQ software is poised to revolutionize how clinicians plan procedures by converting CT angiograms into detailed 3D models of pulmonary vascularization. This will not only aid in better anatomical visualization but will also allow for prioritization of treatment options based on clot characterization data — a crucial advancement in the medical field.

The Importance of TEV Care

TEV represents the third leading cause of cardiovascular-related deaths in the United States, often arising when a blood clot forms in a deep vein, usually in the legs, and disrupts blood flow to the lungs. With such high stakes, Akura Medical's innovations come at a critical time. The organization is dedicated to making a lasting impact on the lives of patients affected by TEV.

About Akura Medical

As a privately-held medical technology company within Shifamed LLC’s portfolio, Akura Medical is laser-focused on revolutionizing the treatment of venous thromboembolism. The Katana™ Thrombectomy System is on track to redefine standards for treating pulmonary embolism by effectively removing various clot types. Akura Medical strives to reform the landscape of TEV care, ensuring a durable impact on patient health in the long run. For more information, visit Akura Medical.

About Shifamed, LLC.

Shifamed is a specialized medical innovation center created by serial entrepreneur Amr Salahieh. It is committed to developing solutions that expedite market entry, mitigate risks, and promote a healthier life for patients worldwide. To explore more about Shifamed, visit Shifamed.

Note: The Katana system is currently for investigational use only and is not approved for sale in the United States or other countries.